Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) can cause cardiac immune-related adverse events (irAEs), including pericarditis. Cardiovascular events related to pericardial irAE are less frequent, but fulminant forms can be fatal. However, the diagnosis and treatment strategies for pericardial irAE have not established.

Case summary

A 58-year-old man was diagnosed with advanced non-small-cell lung cancer and nivolumab was administered as 5th-line therapy. Eighteen months after the initiation of nivolumab, the patient developed limb oedema and increased body weight. Although a favourable response of the cancer was observed, pericardial thickening and effusion were newly detected. He was diagnosed with irAE pericarditis after excluding other causes of pericarditis. Nivolumab w

SUBMITTER: Moriyama S 

PROVIDER: S-EPMC7898560 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature